Immuno-oncology Market, By Treatment Type (Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others), By Disease Type (Melanoma, Lung Cancer, Blood Cancers, Renal Cell Carcinoma, Prostate Cance
Description
Immuno-oncology Market, By Treatment Type (Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others), By Disease Type (Melanoma, Lung Cancer, Blood Cancers, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Other Cancers), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Immuno-oncology involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.
Restraints of the Global Immuno-Oncology Market
Major factors hampering the growth of the immuno-oncology market during the forecast period constitutes of high costs. High cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.
Key features of the study:
This report provides in-depth analysis of the global immuno-oncology market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global immuno-oncology market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global immuno-oncology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Immuno-Oncology Market, By Treatment Type:
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Global Immuno-Oncology Market, By Disease Type:
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
Global Immuno-Oncology Market, By End User:
Hospitals
Clinics
Ambulatory Surgical Centers
Global Immuno-Oncology Market, By Geography:
North America
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
U.S.
Canada
Europe
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Amgen, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
AstraZeneca Plc
Bristol-Myers Squibb Company
Dendreon Corporation (A Sanpower Group Company)
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Ferring Pharmaceuticals
Enzo Biochem, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Immuno-oncology involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.
Restraints of the Global Immuno-Oncology Market
Major factors hampering the growth of the immuno-oncology market during the forecast period constitutes of high costs. High cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.
Key features of the study:
This report provides in-depth analysis of the global immuno-oncology market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global immuno-oncology market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Allergan, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Galapagos, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Inc., AbbVie Inc., Tarsius Pharma, Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global immuno-oncology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Immuno-Oncology Market, By Treatment Type:
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Global Immuno-Oncology Market, By Disease Type:
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
Global Immuno-Oncology Market, By End User:
Hospitals
Clinics
Ambulatory Surgical Centers
Global Immuno-Oncology Market, By Geography:
North America
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
U.S.
Canada
Europe
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Disease Type
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers
By End User
Hospitals
Clinics
Ambulatory Surgical Centers
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Amgen, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
AstraZeneca Plc
Bristol-Myers Squibb Company
Dendreon Corporation (A Sanpower Group Company)
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Ferring Pharmaceuticals
Enzo Biochem, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
188 Pages
- 1. Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Immuno-Oncology Overview
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- PEST Analysis
- PORTER’s Five Forces Analysis
- Mergers & Acquisitions
- Epidemiology
- Research Update & Pipeline Analysis (For each drug category)
- Major FDA Approvals & Product Launch Scenario (For each drug category)
- Regulatory Scenario
- Reimbursement Scenario
- Immunotherapy Combination Therapies In Development
- Adoptive Cell Transfer Therapies
- 4. Global Immuno-Oncology Drugs Market, By Drug Type, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Immune Checkpoint Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- CTL-4 Checkpoint Inhibitor
- Iplimumab
- PD-1 & PD-L1 Checkpoint Inhibitor
- Nivolumab (Opdivo)
- Atezolimumab (Tecentriq)
- Pembrolizumab (Keytruda)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Naked Monoclonal Antibodies
- Rituximab (Rituxan)
- Trastazumab (Herceptin)
- Bevacizumab (Avastin)
- Others
- Conjugated Monoclonal Antibodies
- Radiolabeled Antibodies
- 1. Ibrotumomab Tiuxetan (Zevalin)
- Chemo labeled Antibodies
- 1. Brentixumab Vedotin (Adcetris)
- 2. Trastuzumab Emtansine (Kadcyla)
- Bispecific Monoclonal Antibodies
- 1. Blinatumomab (Blincyto)
- Cytokine Based Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Intron A
- Proleukin
- Cancer Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Preventive Vaccines
- Gardasil
- Cervarix
- Treatment Vaccines
- Sipuleucel-T (Provenge)
- CAR-T Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Kymriah
- Yescarta
- 5. Global Immuno-Oncology Drugs Market, By Cancer Type, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Non-Small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Acute Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Gastric Cancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Glioblastoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Head & Neck Cancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- 6. Global Immuno-Oncology Drugs Market, By Regions, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- North America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Cancer Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- North Africa
- Central Africa
- South Africa
- 7. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Amgen, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene Corporation
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- EMD Serono, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Prometheus Therapeutics & Diagnostics
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aduro BioTech
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galena Biopharma
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bavarian Nordic
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celldex Therapeutics
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ImmunoCellular Therapeutics
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Incyte
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 8. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 25 market data tables and 38 figures on "Immuno-Oncology Drugs Market - Global forecast to 2028”
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
